Drug Kinetics – Products

TetraScience has announced the evolution of its data cloud to include manufacturing and quality control data.

CN Bio today announced the opening of new laboratory facilities at Cambridge Science Park, dedicated to its contract research services.

Biotium has announced the release of new ExoBrite Antibody Conjugates. These antibodies were curated specifically for optimal detection of exosome markers CD9, CD63 and CD81 in isolated exosomes or exosome extracts with little to no background.

Bio-Rad Laboratories, Inc. today extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of antibodies specific to brentuximab vedotin, secukinumab and the secukinumab–interleukin 17A drug-target complex.

NovaXS Biotech Corp, developers of an in-home and needle-free drug delivery platform, for the first time unveiled its new prototype of its needle-free injection therapy smart medical device.

Bio-Rad Laboratories, Inc. has introduced a range of antibodies that are specific to cemiplimab (Libtayo) and inhibit the binding of the drug to its target, human programmed death receptor-1 (PD-1).

Two key ADME (absorption, distribution, metabolism and excretion) properties used to predict the in -vivo performance of a drug candidate are its ability to permeate a cell membrane and its potential to act as a substrate for transmembrane transporter proteins.

Grace will Exhibit at CPhI Worldwide 2021, Virtually and In-Person at Booth 11F26 at Fiero Milano, Milan, Italy.

The utility and efficiency of the Octet® platform at characterizing covalent immune recruiter molecule function and their efficacy as modulators of protein proximity was demonstrated. Efficient in vitro validation further enables the potential acceleration of CIR translation to in vivo model validation and the clinic as a new class of synthetic tumor immunotherapeutic.

Innovative predictive methods support virtual screening and compound design in the absence of 3D structure data.